BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
1/10/2023 8:49:38 AM | Browse: 255 | Download: 706
 |
Received |
|
2022-09-16 15:27 |
|
Peer-Review Started |
|
2022-09-16 15:29 |
 |
To Make the First Decision |
|
|
|
Return for Revision |
|
2022-10-20 14:34 |
|
Revised |
|
2022-11-03 07:29 |
|
Second Decision |
|
2022-12-07 03:23 |
|
Accepted by Journal Editor-in-Chief |
|
|
|
Accepted by Executive Editor-in-Chief |
|
2022-12-07 18:13 |
|
Articles in Press |
|
2022-12-07 18:13 |
|
Publication Fee Transferred |
|
|
|
Edit the Manuscript by Language Editor |
|
2022-12-11 19:14 |
|
Typeset the Manuscript |
|
2023-01-03 06:20 |
|
Publish the Manuscript Online |
|
2023-01-10 08:49 |
| ISSN |
1948-5204 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Gastroenterology & Hepatology |
| Manuscript Type |
Review |
| Article Title |
Roles of conventional and complementary therapies in recurrent hepatocellular carcinoma
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
Hsiang-Chun Lai, Hung-Jen Lin, Long-Bin Jeng and Sheng-Teng Huang |
| ORCID |
|
| Funding Agency and Grant Number |
| Funding Agency |
Grant Number |
| Ministry of Science and Technology of Taiwan |
NSTC111-2320-B-039-025 |
| China Medical University Hospital |
DMR-111-005 |
| China Medical University Hospital |
DMR-111-013 |
| China Medical University Hospital |
DMR-111-016 |
| China Medical University Hospital |
DMR-111-195 |
| An-Nan Hospital, China Medical University |
ANHRF-110-25 |
|
| Corresponding Author |
Sheng-Teng Huang, MD, PhD, Chief Doctor, Professor, Staff Physician, Department of Chinese Medicine, China Medical University Hospital, No. 2 Yude Road, North District, Taichung 40447, Taiwan. sheng.teng@yahoo.com |
| Key Words |
Recurrence; Hepatocellular carcinoma; Complementary therapy; Traditional Chinese medicine; Cancer stemness; Drug resistance |
| Core Tip |
Studies report a recurrence rate for hepatocellular carcinoma of up to 70%-80% after 5 years of follow-up. Controlling tumor recurrence is the most critical factor associated with hepatocellular carcinoma (HCC) mortality. Although, conventional salvage therapies, including re-hepatectomy, transcatheter arterial chemoembolization, target therapy, immunotherapy have yet to achieve favorable outcomes. Complementary therapies as an adjuvant treatment modality may strengthen and augment conventional therapies. We herein discuss the molecular mechanisms underlying complementary therapies and the interactions with conventional therapy in recurrent HCC related to augmenting the local control, inhibiting epithelial-mesenchymal transition, migration, invasion, metastasis and cancer stem cells, and by ameliorating drug resistance. |
| Publish Date |
2023-01-10 08:49 |
| Citation |
Lai HC, Lin HJ, Jeng LB, Huang ST. Roles of conventional and complementary therapies in recurrent hepatocellular carcinoma. World J Gastrointest Oncol 2023; 15(1): 19-35 |
| URL |
https://www.wjgnet.com/1948-5204/full/v15/i1/19.htm |
| DOI |
https://dx.doi.org/10.4251/wjgo.v15.i1.19 |
© 2004-2025 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345
